

RESEARCH AND REVIEWS: JOURNAL OF PHARMACEUTICS AND NANOTECHNOLOGY

Formulation and Evaluation of Propranolol Hydrochloride Microspheres.

Kanaka Durga Vikash Guntiboyina^{1*}, Sanjay P Umachigi¹, Prasanth VV¹, Abhishek Sharma¹, Rinku Mathappan², and Sam T Mathew³.

¹Department of Pharmaceutics, Gautham College of Pharmacy, Bangalore, 560 032, India.

³Department of Pharmacognosy, Gautham College of Pharmacy, Bangalore, 560 032, India.

³Regulatory affairs and Medical writing, Biocon Pvt Ltd, Bangalore 560 100, India.

Research Article

Received: 03/01/2014

Revised: 22/02/2014

Accepted: 04/03/2014

*For Correspondence

Department of Pharmaceutics,
Gautham College of Pharmacy
Sulthan Palaya, R.T Nagar Post
Bangalore, Karnataka, India.

Keywords: Accelerated stability studies, Higuchi, Korsmeyer-Peppas, Propranolol Hydrochloride, Particle size, Scanning electron microscopy

ABSTRACT

Six formulations of Propranolol Hydrochloride loaded microspheres were prepared by non-aqueous emulsification-solvent evaporation technique. The percentage yield of the microspheres varied from 75.33 ± 0.006 and 92.21 ± 0.003 . The entrapment efficiency of Propranolol Hydrochloride microspheres were ranged between 79.7 ± 0.02 and 85.87 ± 0.03 %. It was reported that the encapsulation efficiency depends on the solubility of the drug in the solvent. The mean particle size of the prepared formulation ranged from 256.56 ± 0.07 and $382.77 \pm 0.05 \mu\text{m}$. The drug content of the prepared formulation ranged between 76.19 ± 2.5 and 87.74 ± 3.1 %. The swelling indices of the microspheres were high (up to 0.89 ± 0.02 for F4) and varied between the formulations. The maximum *in vitro* release was evaluated to be 96.55 % over a period of 14 h for formulation F4. The *in vitro* drug release increased in the following order: F1 < F6 < F3 < F5 < F2 < F4. Formulations F6 provided good fit to the Higuchi model and the remaining formulations showed the best fit to the Korsmeyer-Peppas model. Scanning electron micrographs of selected formulation indicated that the microspheres were discrete, uniform and spherical with a smooth surface. During at the end of accelerated stability studies the tested formulation (F4) showed non-significantly different drug content, entrapment efficiency and *in vitro* drug release from that observed at the beginning of the study. No color changes were also observed during the study period.

INTRODUCTION

Oral drug delivery is the most attractive and favored manner of drug delivery for achieving mutually systemic and local therapeutic effects. But a variety of problems are also related with the conventional oral dosage forms, that it is frequently essential to take several times per day to retain the concentration of administered drug within the therapeutically effective range which results in a fluctuated drug level and consequently undesirable toxicity and poor efficiency. So to overcome such problems associated with conventional oral dosage form, the idea of controlled drug delivery systems was introduced [1]. The real challenge in the development of a controlled drug delivery system is not just to control the drug release, also to extend the existence of the dosage form in the absorption site until all the drug is completely released in the preferred period of time [2-4]. Continuous release of the drug involves polymers that release the drug at a controlled manner due to the degradation of polymer over time and it can be achieved by using drug carrying polymer.

Propranolol Hydrochloride is a beta-adrenergic blocking drug, which is widely used in the treatment of cardiovascular diseases, particularly in the treatment of weak and moderate hypertension, angina pectoris, ventricular arrhythmia, hypertrophic subaortic stenosis, etc [5]. It was the first successful beta blocker developed [6]. Propranolol Hydrochloride is highly lipophilic and is almost completely absorbed after oral administration. Its oral bioavailability of Propranolol Hydrochloride is approximately 26% and half life is almost 3-4hour [7]. Moreover, the site of absorption of Propranolol Hydrochloride stomach and dosage forms that are retained in the stomach would increase the absorption, improve drug efficiency, and decrease dose requirements [8].

The aim of the present work was to formulate an alternative controlled release formulation of Propranolol Hydrochloride to retain the dosage form in the absorption site more than the half life of the drug, to improve the bioavailability, reduce dose frequency, toxicity and patient compliance.

MATERIALS AND METHODS

Preparation of Propranol Hydrochloride Microspheres

The compositions of different Propranol Hydrochloride microspheres are shown in Table 1. Microparticles containing Propranolol Hydrochloride as the core material was prepared by a solvent evaporation method using water and ethanol as solvent^[9]. The drug, solvent and polymers were mixed at (1:2) ratios. The polymer solution was slowly introduced into 40 mL of liquid paraffin while being stirred at 700 rpm using a mechanical stirrer equipped with a three bladed propeller at room temperature. The solution was stirred for 2 hr to allow the solvent to evaporate completely and the microcapsules were collected by filtration. The microcapsules were washed repeatedly with petroleum ether (40-60°C) until free from oil. The collected microcapsules were dried for 1 hr at room temperature and subsequently stored in a desiccator over fused CaCl₂ until further study.

Table 1. Compositions of Different Propranol Hydrochloride Microspheres

Ingredients	Formulation Code					
	F1	F2	F3	F4	F5	F6
Propranolol Hydrochloride (mg)	40	40	40	40	40	40
Gelatin (mg)	80	-	-	-	40	-
Chitosan (mg)	-	80	-	-	-	40
Ethyl cellulose (mg)	-	-	80	-	40	-
HPMC (mg)	-	-	-	80	-	40
Span 80 (mL)	1	1	1	1	1	1
Liquid paraffin (mL)	40	40	40	40	40	40

Evaluations

Micromeritic Properties

Microspheres were characterized for micromeritic properties such as bulk density, tapped density, compressibility index, Hausner's ratio, and angle of repose^[10-11]. The tapping method was used to determine the tapped density in which the cylinder containing known amount (M) of microspheres was subjected to a fixed number of taps (approximately 100) until the bed of microspheres had reached the minimum. The final volume after tapping 'V_o' was recorded and the tap density was calculated by the following equation:

$$\text{Tapped density (P}_p\text{)} = M/V_o$$

Angle of repose, Hausner ratio, and Carr index (% compressibility index) were determined to predict flowability. A higher Hausner ratio indicates greater cohesion between particles, while high Carr index is indicative of the tendency to form bridges. Angle of repose of the microspheres, is the maximum angle possible between the surface of the pile of microspheres and the horizontal plane, was obtained by fixed funnel method using the formula;

$$\text{Angle of repose } (\theta) = \text{Tan}^{-1}(2h/d)$$

Where, h is height and d is the diameter of the microsphere pile that is on a paper after making the microspheres flow from the glass funnel. Hausner ratio and Carr index were calculated using the formulae:

$$\text{Carr index or \% compressibility index or C} = [1 - (V_o/V)] \times 100$$

Here, V and V_o are the volumes of the sample before and after the standard tapping, respectively and C is Carr index.

Determination of Encapsulation Efficiency (EE) and Percentage Yield of Microspheres

To determine the amount of Propranol Hydrochloride encapsulated in microspheres, a known weight of microspheres was weighed into screw-capped vials with phosphate buffer (pH 6.8) and digested by sonicating the sample for 10 minutes and subsequently keeping the sample aside for 10 minutes. This procedure was repeated thrice (i.e. 30 min sonication) in order to extract the entrapped drug completely. The absorbance was noted at 219 nm using a double-beam spectrophotometer (UV 1800 Shimadzu, Kyoto, Japan) after diluting suitably with distilled water. Blank microspheres treated in a similar manner were used as the blank^[12]. The percentage of encapsulation efficiency was calculated by the following formula.

$$\%EE = (ED/AD) \times 100$$

Where, %EE is the percentage encapsulation efficiency; ED is the amount of encapsulated drug; and AD is the amount of added drug. The percentage yield of microspheres was calculated using the following formula.

$$\text{Percentage Yield} = (\text{Practical Yield} / \text{Theoretical Yield}) \times 100$$

Particle Size

The particle size of the albumin microspheres was analyzed by laser particle size analyzer (Malvern Instruments, Mastersizer 2000, Malvern, UK) using n-Hexane as dispersant. The sample was vortexed for 1 minute before sampling. The samples were then sonicated in a sonicator attached to the instrument throughout the process, and the duration of sonication was kept constant for all samples. The obscuration value was observed as 14.87%. Volume of distribution was plotted using a computer program supplied by the manufacturer. Polydispersity was calculated by the following equation^[13]:

$$\text{Polydispersity} = [D(0.9) - D(0.1)] / D(0.5)$$

Where D(0.9), D(0.5), and D(0.1) are the particle diameters determined respectively at the 90th, 50th, and 10th percentile of undersized particles.

Swelling Index

The swelling of microspheres were carried out in phosphate buffer (pH 6.8) for 14 hrs. The excess liquid drops adhered to surface were removed by blotting and the swollen microspheres were weighed. The microspheres were then dried in hot air oven at 40°C for 60 hrs until there was no change in dried mass of sample. The swelling index was calculated from the following equation^[14].

$$SI = \frac{\text{Mass of swollen microspheres} - \text{mass of dry microspheres}}{\text{Mass of dried microspheres}}$$

Drug Content

Crushed microparticles 40 (mg) were vortex-mixed for 2 hours with phosphate buffer (pH 6.8). The extract was transferred to a 25 mL volumetric flask and the volume made up using water. The concentration was measured by UV spectrophotometer at 219 nm against appropriate blank. The amount of drug entrapped in the microparticles was calculated^[15].

In-vitro Drug Release Study

In-vitro release studies were carried out for the formulations in dissolution test apparatus USP type II^[16]. Microparticles equivalent to 100 mg of the pure drug were used. 900 mL of phosphate buffer (pH 6.8) was used as the dissolution medium and then same volume of phosphate buffer (pH 6.8) was replaced in the dissolution apparatus for 14 h, at 50 rpm at 37 ± 0.5°C. One ml of the aliquot was withdrawn at different predetermined time intervals (1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0 and 14.0 h), and replaced with an equal volume of fresh dissolution medium to maintain constant volume. The samples were filtered through 0.45 µm filter and appropriately diluted with phosphate buffer (pH 6.8) and assayed spectrophotometrically at 219 nm. The mechanism of drug release from the microspheres was determined by finding the best fit of the release data to Higuchi and Korsmeyer-Peppas plots. The release rate constants k and n of each model were calculated by linear regression analysis using Microsoft Excel 2003 software. Coefficients of determination (R^2) were used to evaluate the accuracy of the fit^[17-18].

Scanning Electron Microscopy (SEM)

The surface morphology of pure drug was examined by (JOEL JSM T330A) scanning electron microscope. The sample was examined and photographed under various magnifications with direct data capture of the images onto a computer.

Accelerated Stability Studies

Accelerated stability study was carried out for six months for the selected formulations. The optimized formulations were packed in polyvinyl dichloride blister packing and loaded into stability chamber and were maintained at 40 ± 2 °C/75 ± 5% temperature and relative humidity respectively. The samples were withdrawn at

monthly intervals and checked for particle size, drug content, entrapment efficiency and *in vitro* drug release studies (ICH Q1A R2 2003).

RESULT AND DISCUSSION

Formulation Studies

In the present study, a total of 6 formulations of Propranolol Hydrochloride loaded microspheres were prepared by non-aqueous emulsification-solvent evaporation technique using different polymers like gelatin, ethyl cellulose, chitosan and HPMC.

Micromeritic properties

Flow properties of selected microspheres were evaluated by measuring the angle of repose, Hausner's ratio, bulk density, tapped density and compressibility index is shown in Table 2. The Angle of repose ranged between $21^\circ.10' \pm 1.1$ and $22^\circ.27' \pm 1.4$, bulk density varied between 0.322 ± 1.2 and 0.398 ± 0.6 g/mL and tapped density lies between 0.418 ± 2.2 and 0.482 ± 1.7 g/mL. The compressed index was found between 6.87 ± 1.3 and 8.78 ± 1.2 and Hausner ratio lies between 1.032 ± 1.8 and 1.089 ± 3.1 . All tested microspheres showed excellent flowability with angle of repose being less than 23° . The compressibility of the tested microspheres was less than 7%. It was reported that when compressibility is below 9% and the angle of repose is within 25° the powder show good flowability and do not require any glidants to improve the bioavailability. It was reported that powders with a Hausner's ratio lesser than 1.25 is considered to be possessing good flowability.

Table 2. Micromeritic properties of Propranolol Hydrochloride Microspheres

Formulations	Angle of Repose (θ)*	Bulk density (g/ml)*	Tapped density (g/ml)*	Compressibility Index (%)*	Hausner Ratio*	LOD (%)*
F1	$22^\circ.11' \pm 1.2$	0.322 ± 1.2	0.423 ± 1.2	8.18 ± 2.1	1.064 ± 1.2	3.2 ± 1.2
F2	$21^\circ.10' \pm 1.1$	0.387 ± 0.3	0.418 ± 2.2	7.56 ± 1.8	1.054 ± 2.2	3.0 ± 0.8
F3	$22^\circ.17' \pm 1.3$	0.390 ± 1.2	0.434 ± 1.6	6.87 ± 1.3	1.032 ± 1.8	2.8 ± 2.2
F4	$22^\circ.11' \pm 1.2$	0.379 ± 1.3	0.443 ± 2.1	8.78 ± 1.2	1.089 ± 3.1	3.3 ± 1.4
F5	$21^\circ.18' \pm 1.2$	0.376 ± 1.5	0.454 ± 1.4	7.54 ± 3.2	1.065 ± 2.2	2.9 ± 1.3
F6	$22^\circ.27' \pm 1.4$	0.398 ± 0.6	0.482 ± 1.7	8.42 ± 1.8	1.042 ± 3.1	3.1 ± 2.1

Determination of Encapsulation Efficiency (EE) and Percentage Yield of Microspheres

The percentage yield and encapsulation efficiency of Propranolol Hydrochloride microspheres are shown in Table 3. The percentage yield of the microspheres varied from 75.33 ± 0.006 and 92.21 ± 0.003 . The effect of different factors on the percentage yield of microspheres was not clear, possibly due to an improper recovery of microspheres from the filter paper. Entrapment efficiency is an important parameter for microspheres and it gives a measure of the robustness of the formulation technique. Drug may get entrapped into the core of the spherical matrix, polymer matrix or may be loosely bound to the surface. The entrapment efficiency of Propranolol Hydrochloride microspheres were ranged between 79.7 ± 0.02 and 85.87 ± 0.03 %. It was reported that the encapsulation efficiency depends on the solubility of the drug in the solvent. In the current study, the drug was highly soluble in the solvent (water) and slightly soluble in the continuous phase (light liquid paraffin). The solubility of Propranolol Hydrochloride in light liquid paraffin could be one of the reasons for lesser entrapment efficiency. This inference could not be confirmed since the drug present in the paraffin washings was not quantified. However, relation between other processing parameters and entrapment efficiency was unclear.

Table 3. The percentage Yield and Encapsulation Efficiency of Propranolol Hydrochloride Microspheres

Formulation code	Percentage yield (%)	Drug Entrapment Efficiency (%)
F1	81.80 ± 0.004	81.66 ± 0.04
F2	83.40 ± 0.006	83.54 ± 0.02
F3	79.55 ± 0.007	82.32 ± 0.06
F4	92.21 ± 0.003	85.87 ± 0.03
F5	76.16 ± 0.004	79.76 ± 0.02
F6	75.33 ± 0.006	81.42 ± 0.01

Mean \pm SD, n=3

Particle Size and Drug Content

The data for particle size and drug content is shown in Table 4. The microspheres could not reveal a unimodal size distribution curve. The mean particle size of the prepared formulation ranged from 256.56 ± 0.07 and $382.77 \pm 0.05 \mu\text{m}$. The drug content of the prepared formulation ranged between 76.19 ± 2.5 and $87.74 \pm 3.1\%$.

Table 4. The Mean Particle Size and Drug Content of Propranolol Hydrochloride Microspheres


Formulation code	Particle size (μm)	Drug content (%)
F1	256.56 ± 0.07	78.47 ± 1.1
F2	379.45 ± 0.03	80.37 ± 2.1
F3	284.48 ± 0.01	79.91 ± 4.1
F4	382.77 ± 0.05	87.74 ± 3.1
F5	326.50 ± 0.03	76.19 ± 2.5
F6	302.50 ± 0.04	81.98 ± 1.5

Mean \pm SD, n=3

Swelling Index

The swelling index of the prepared formulations is shown in Figure 1. The swelling indices of the microspheres were high (up to 0.89 ± 0.02 for F4) and varied between the formulations. Higher swelling indices may be due to the presence of water soluble polymers. The swelling behavior provides an indication of the relative moisture absorption capacities of polymers and whether the formulations maintain their integrity after absorption of moisture. Differences in swelling of the tested hydrophilic polymers could be explained by the difference in resistance of the matrix network structure (hydrogen bond) to the movement of water molecules. The swelling indices increased in the following order: F3 < F5 < F6 < F1 < F2 < F4.


Figure 1: Swelling Index of Propranolol Hydrochloride Microspheres



In-vitro Drug Release Study

The *in vitro* drug release of Propranolol Hydrochloride microspheres is shown in Figure 2. The release of drug from the formulation depends on the type and concentration of polymer used and the pH of the dissolution medium. The release of Propranolol Hydrochloride from different formulations was carried out in phosphate buffer (pH 6.8). The maximum *in vitro* release was evaluated to be 96.55% over a period of 14 h for formulation F4. The *in vitro* drug release increased in the following order: F1 < F6 < F3 < F5 < F2 < F4. The drug release mechanism from controlled release devices is very complex, and not yet completely understood. Although some processes may be classified as either purely diffusion or purely erosion controlled, many others can only be interpreted as being governed by both. The R^2 , 'k' and 'n' values are given in Table 5. From the drug release profile we have selected formulation F4 as the best formulation and used for further studies such as scanning electron microscopy and accelerated stability studies.

Figure 2. *In Vitro* Drug Release of Propranolol Hydrochloride Microspheres



Formulations F6 provided good fit to the Higuchi model. According to this model, the drug release from these patches may be controlled by diffusion through the micropores. The remaining formulations showed the best fit to the Korsmeyer-Peppas model showed super case II transport drug release. This mechanism could result from increased plasticization at the relaxing boundary.


Table 5: R^2 , 'k' and 'n' values of Propranolol Hydrochloride Microspheres

Formulations	Higuchi		Korsmeyer-Peppas		Mechanism of drug release
	R^2	k ($h^{-1/2}$)	R^2	n	
F1	0.9886	18.166	0.992	4.1604	Super case II transport
F2	0.9896	18.469	0.9969	1.0162	Super case II transport
F3	0.9916	18.145	0.9994	1.0070	Super case II transport
F4	0.9821	18.764	0.9868	1.0444	Super case II transport
F5	0.9844	19.154	0.9917	1.0535	Super case II transport
F6	0.9949	18.633	0.9937	1.0330	Diffusion

Scanning Electron Microscopy

Scanning electron micrographs of selected formulation is shown in Figure 3. The result indicated that the microspheres were discrete, uniform and spherical with a smooth surface. The particles appear to be in the form of aggregates. The aggregate formation may be due to insufficient washings.

Figure 3. Scanning Electron Micrographs of Selected Propranolol Hydrochloride Microspheres (F4)



Accelerated Stability Studies

The accelerated stability study of selected formulation is shown in Table 6. During the evaluation, the tested formulation (F4) showed non-significantly different drug content, entrapment efficiency and *in vitro* drug release from that observed at the beginning of the study. No color changes were also observed during the study period.

Table 6: The accelerated stability study of selected Propranolol Hydrochloride Microspheres (F4)

Evaluation Parameter	Formulation code	1 st month	3 rd month	5 th month	6 th month
Appearance	F4	No change	No change	No change	No change
Entrapment efficiency (%)*	F4	85.12 ± 0.01	84.21 ± 0.04	84.11 ± 0.05	83.12 ± 0.07
Drug content (%)*	F4	87.23 ± 2.0	86.14 ± 1.1	85.91 ± 3.2	85.42 ± 2.8
<i>In vitro</i> drug release (%)*	F4	96.55 ± 3.1	96.12 ± 2.1	95.98 ± 1.1	95.21 ± 1.8

Mean ± SD, n=3

CONCLUSION

The microspheres of Propranolol Hydrochloride were prepared by solvent casting method to ensure satisfactory drug release, enhance improved bioavailability, reduce dose and frequency of administration and also to release the drug from the formulation in a controlled manner. From this study, it is concluded that, the microspheres of Propranolol Hydrochloride can be formulated using chitosan, HPMC, gelatin and ethyl cellulose. The *in vitro* studies have shown that this is a potential drug delivery system for Propranolol Hydrochloride with a considerably good stability and release profile. Future studies are warranted to confirm these results *in vivo*.

REFERENCES

1. Aithal KS, Udupa N. Preparation and evaluation of alginate microspheres containing norfloxacin and ciprofloxacin. *Indian J Pharma Sci.* 1997; 59(2): 61-67.
2. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. Chitosan microspheres as a potential carrier for drugs. *Int J Pharm* 2004; 274: 1-33.
3. Samanta MK, Tamilvanan S, BabuK, SureshSB. Formulation and evaluation of Chlorpromazine hydrochloride loaded self-cross linked gelatin microcapsules. *Indian J Pharm Sci* 1997; 59(2): 68-74.
4. Shukla JB, Patel NS, Patel GC. Formulation design and optimization of bucco-mucoadhesive bilayered tablet of Propranolol hydrochloride. *International Journal of Pharma and Bio Sciences* 2010; 1 (2): 1-10.
5. Patel VM, Prajapati BG, Patel MM. Design and characterization of chitosan containing mucoadhesive buccal patches of propranolol hydrochloride. *Acta Pharm* 2007; 57: 61-67.
6. Patel VM, Prajapati BG, Patel MM. Effect of hydrophilic polymers on bucco-adhesive Eudragit patches of propranolol hydrochloride using factorial design. *AAPS Pharm Sci Tech* 2007; 8(2): E119-126.
7. DeelipDerle, Omkarjoshi, AshishPawar, Jatin Patel, AmolJagadale. Formulation and Evaluation of Bucco-adhesive bi-layer tablet of propranolol hydrochloride. *Int J Pharmacy and Pharmaceutical Sci* 2009; 1(1): 206-212.
8. Deshpande KB, More MR. Formulation and evaluation of orodispersible tablets of propranolol hydrochloride. *Int J Pharm Res Development* 2011; 2(12): 46-52.
9. Mathiowitz E. *Encyclopedia of controlled drug delivery*. Canada: John Wiley and Sons; 1999:493-543.
10. Leon Lachman, Herbert Liberman A, Joseph Kanig L. *The theory and practice of Industrial Pharmacy*, 3rd edition. Varghese Publishing house, Bombay, 1998: 183-184, 296, 300-301.
11. Subrahmanyam CVS. *Textbook of Physical Pharmaceutics*. 2 edition, VallabhPrakashan, 2000; 222-224.
12. Leon Lachman, Herbert A Liberman, Joseph L Kanig. *Micromeritics and coating of capsule*, in "Theory and Practice of Industrial Pharmacy", 2nd edition; Lea &Febiger, Philadelphia; 425-436.
13. Robert HP, Green DW, Malone JO. *Perry's chemical engineers handbook*. 6thed. Malaysia: McGraw hill Book Co; 1984:21/14-21/19.
14. Dandagi PM, Mastiholimath VS, Gadad AP, Iliger SR. Mucoadhesive microspheres of propranolol hydrochloride for nasal delivery. *Ind J Pharm Sci* 2010; 69(3): 402-407.
15. Satit P, Thaned P, Aroonsri P. Molecular interaction in alginate beads reinforced with sodium starchglycolate or magnesium aluminum silicate and their physical characteristics. *Int J Pharm* 2005; 293: 51-62.
16. Paulo Costa, Jose Manuel Sousa Lobo. Modeling and comparison of dissolution profiles. *Eur J Pharm* 2001; 13: 123-133.

17. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J PharmSci 1961; 50: 874 - 875.
18. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of potassium chloride release from compressed, hydrophilic, polymeric matrices: Effect of entrapped air. J Pharm Sci 1983; 72: 1189 - 1191.